Canine Arthritis Treatment Market: Asia Pacific Excluding Japan to Register the Fastest Growth During the Forecast Period: Global Industry Analysis (2013 - 2017) and Opportunity Assessment (2018 - 2028)

Canine Arthritis Treatment Market: Asia Pacific Excluding Japan to Register the Fastest Growth During the Forecast Period: Global Industry Analysis (2013 - 2017) and Opportunity Assessment (2018 - 2028)

Future Market Insights (FMI) offers a 10-year forecast on the global canine arthritis treatment market. The primary objective of the report is to offer updates and information related to market opportunities in the canine arthritis treatment market.

Report Description

In terms of revenue, the global canine arthritis treatment market is expected to register a CAGR of 4.4% during the forecast period, 2018–2028. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global canine arthritis treatment market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global canine arthritis treatment market are presented in the report.

The global market for canine arthritis treatment is expected to witness high growth rate in terms of value in high economic countries due to fast FDA approvals for novel and innovative canine arthritis treatment drugs coupled with growing adoption of stem therapy to treat arthritis. Additionally, huge investments in the research and development sector for the development of advanced stem cell therapy and drugs for arthritis in countries such as the U.S., Germany, France and U.K. is expected to create numerous opportunities for the manufacturers of canine arthritis treatment products. Manufacturers are focusing on the production of high-grade drugs with less side effects due to its high demand from end users.

The report includes canine arthritis treatment drugs such as non-steroidal anti-inflammatory medications (NSAIDs) and opioids. Also, the stem cell therapy is taken into account along with drugs to calculate revenue generation in the canine arthritis treatment market.

However, the report does not include revenue generated by the sale of other medical products such as prosthetics and medical devices. Currency fluctuations and inflation are not considered while calculating the revenue of the canine arthritis treatment market

Revenue from the canine arthritis treatment market in North America is expected to expand at the relatively higher CAGR due to growing adoption of drugs and therapies and increased consumer spending on veterinary care. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the treatment type, route of administration, end users and regions. The report provides analysis of the global canine arthritis treatment market in terms of market value (US$ Mn).

The global canine arthritis treatment market is segmented on the basis of treatment type into:

Non-steroidal anti-inflammatory drugs
Opioids
Stem Cell Therapy
The report begins with the market definition of canine arthritis treatment, followed by definitions of the different treatment types. The market dynamics section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global canine arthritis treatment market.

The report analyses the canine arthritis treatment market on the basis of the route of administration and end users and presents forecast in terms of value for the next 10 years. On the basis of route of administration, the global canine arthritis treatment market is segmented into:

Oral

Injectable

On the basis of the end users, the global canine arthritis treatment market is segmented into:

Veterinary Hospitals and Clinics

Retail Pharmacies

Drug Stores

E-commerce

Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. On the basis of region, the global canine arthritis treatment market is segmented into:

North America

U.S.

Canada

Latin America

Brazil

Mexico

Rest of Latin America

Europe

Germany

France

U.K.

Italy

Spain

Russia

Rest of Europe

Asia Pacific

India

China

Australia & New Zealand

ASEAN

Rest of APEJ

Japan

Middle East & Africa (MEA)

GCC Countries

South Africa

Rest of MEA

In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global canine arthritis treatment market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the canine arthritis treatment market. To understand the key segments in terms of their growth and performance in the global canine arthritis treatment market, Future Market Insights has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in canine arthritis treatment market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global canine arthritis treatment market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the canine arthritis treatment market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global canine arthritis treatment market.

Detailed profiles of canine arthritis treatment drug manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the canine arthritis treatment market are Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, among others.